TSTickerStarGet alerts

STRO Q3 2026 STRO-006 Phase 1 Initiation First patient dosed in October 2026, Beat Guidance by +2023.0

STRO beat prior Q3 2026 STRO-006 Phase 1 Initiation guidance by +2023.0. Sutro Biopharma reported Q3 2026 revenue of $9.1 million, down 6% year-over-year from $9.7 million in Q3 2025, with the decrease driven by lower collaboration revenue. Net loss improved to $31.5 million or -$1.90 per share compared to a net loss of $56.9 million or -$6.66 per share in the prior-year period. The company initiated STRO-006 Phase 1 with first patient dosed in October 2026, meeting its Q3 2026 guidance milestone, and expects it...

Share this story

Guidance comparison

STRO-006 Phase 1 InitiationQ3 2026
First patient dosed in October 2026Guide Q3 2026 | beat | +2023.0 | +67433.3%

Key takeaways

  • STRO-006 Phase 1 was initiated with the first patient dosed in October 2026, satisfying the Q3 2026 guidance milestone; initial data are expected in the second half of 2027.

  • Astellas dosed the first patient in its second dual-payload iADC program, triggering a $10 million milestone payment that Sutro received in October 2026.

  • Revenue of $9.1 million fell 6% from $9.7 million in Q3 2025, with the decline attributed to lower collaboration revenue; no other revenue drivers were disclosed.

  • Lower spending drove the narrower loss: total operating expenses fell to $31.0 million from $58.2 million, with R&D at $23.5 million versus $39.9 million and G&A at $7.5 million.

  • Cash, cash equivalents and marketable securities of $142.2 million as of September 30, 2026 are expected to support operations into the first half of 2028.

  • Loss from operations was $22.0 million, down 55% year-over-year.

  • Fireside chat appearances are scheduled for the UBS Global Biopharma Conference (November 17, 2026, 10:40 AM GMT), the Jefferies Global Healthcare Conference (November 18, 2026, 1:30 PM GMT) and the Piper Sandler 38th Annual Healthcare Conference (December 2, 2026, 1:30 PM EST), all in London or New York.

Key metrics

Total RevenueQ3 2026
$9.1 million-6%
Net LossQ3 2026
$31.5 million-45%
Net Loss Per Share (Basic and Diluted)Q3 2026
-$1.9071% improvement
Loss from OperationsQ3 2026
$22.0 million-55%
Total Operating ExpensesQ3 2026
$31.0 million-47%
Research and Development ExpensesQ3 2026
$23.5 million-41%
General and Administrative ExpensesQ3 2026
$7.5 million-14%
Cash, Cash Equivalents and Marketable SecuritiesSeptember 30, 2026
$142.2 million

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow STRO in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert